Autor Deborah M. 4

What Happened Deborah M. Autor, a director of Amneal Pharmaceuticals (AMRX), had 34,819 restricted stock units (RSUs) vest and convert into common shares on May 7, 2026. The filing shows the RSU conversion (derivative exercise/conversion) and a corresponding disposition of 34,819 shares at $0, plus a separate grant of 19,824 RSUs recorded May 6, 2026. No cash purchase or open-market sale is reported; no cash value is shown for the converted/disposed shares.

Key Details

• Transaction types/dates:
  • 2026-05-07: Exercise/conversion of 34,819 RSUs into shares (transaction code M). Price reported N/A for the acquisition.
  • 2026-05-07: Disposition of 34,819 shares at $0 (reported as derivative disposition).
  • 2026-05-06: Grant/award of 19,824 RSUs (derivative) at $0.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes:
  • F1: Each RSU represents a contingent right to one share of Class A common stock.
  • F2: The 34,819 RSUs were originally granted on May 6, 2025 and vested on May 7, 2026.
  • F3: Vesting occurs on the later of the day before the issuer's first annual meeting following grant or the day after the first anniversary of grant.
• The reported $0 disposition is consistent with company share withholding to satisfy tax obligations on vested RSUs (common practice), rather than an open-market sale.
• Filing timeliness: Form 4 was filed May 8, 2026 for transactions dated May 6–7, 2026; this appears to be filed within the standard two‑business‑day reporting window.

Context RSU vesting and conversion are derivative transactions that convert a contingent award into actual shares; they do not necessarily signal buying or selling intent. Often the company withholds shares to cover taxes at vesting, which looks like a $0 disposition on the Form 4. This filing documents vesting and a new RSU grant, not an open‑market trade.